AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley and is headquartered in Menlo Park, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Readnour Robin Shane | Director | Nov 27 '24 | Buy | 1.42 | 50,000 | 70,840 | 622,573 | Nov 27 07:07 PM | Readnour Robin Shane | Director | Nov 26 '24 | Buy | 1.39 | 25,000 | 34,845 | 597,573 | Nov 27 07:07 PM | Zakrzewski Joseph S | Director | Nov 27 '24 | Buy | 1.40 | 2,000 | 2,800 | 125,199 | Nov 27 04:16 PM | Readnour Robin Shane | Director | Nov 19 '24 | Buy | 1.04 | 150,000 | 155,258 | 560,073 | Nov 21 06:00 PM | Readnour Robin Shane | Director | Nov 20 '24 | Buy | 1.16 | 50,000 | 57,870 | 585,073 | Nov 21 06:00 PM | Zakrzewski Joseph S | Director | Nov 18 '24 | Buy | 1.00 | 20,000 | 19,996 | 118,199 | Nov 20 04:11 PM | Zakrzewski Joseph S | Director | Nov 19 '24 | Buy | 1.01 | 5,000 | 5,050 | 123,199 | Nov 20 04:11 PM | Easom Eric | Chief Executive Officer | Nov 18 '24 | Buy | 1.00 | 50,000 | 49,970 | 1,065,766 | Nov 18 08:51 PM | RA Capital Healthcare Fund LP | Affiliate | Aug 15 '24 | Proposed Sale | 1.00 | 1,699,998 | 1,699,999 | | Aug 15 05:39 PM | RA Capital Nexus Fund II, L.P. | Affiliate | Aug 15 '24 | Proposed Sale | 1.02 | 299,999 | 305,998 | | Aug 15 05:34 PM | Leonard Braden Michael | 10% Owner | Aug 14 '24 | Buy | 1.04 | 1,500,000 | 1,560,000 | 5,749,432 | Aug 14 08:24 PM | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Aug 09 '24 | Sale | 1.08 | 3,525,094 | 3,807,102 | 300,853 | Aug 13 05:03 PM | Zakrzewski Joseph S | Director | Jan 18 '24 | Sale | 19.11 | 100,000 | 1,911,410 | 405,880 | Jan 19 07:32 PM | Aziz Kabeer | Director | Jan 16 '24 | Sale | 19.65 | 100,000 | 1,965,000 | 377,542 | Jan 18 06:19 PM | Adjuvant Global Health Technol | 10% Owner | Jan 16 '24 | Sale | 19.65 | 84,093 | 1,652,427 | 1,995,958 | Jan 18 06:18 PM | Adjuvant Global Health Technol | 10% Owner | Jan 16 '24 | Sale | 19.65 | 15,907 | 312,573 | 377,542 | Jan 18 06:18 PM | Readnour Robin Shane | Director | Jan 12 '24 | Sale | 21.91 | 1,425 | 31,229 | 414,788 | Jan 17 05:03 PM | Readnour Robin Shane | Director | Jan 10 '24 | Sale | 21.93 | 3,669 | 80,443 | 415,494 | Jan 12 05:08 PM | Krause Kevin Michael | Chief Strategy Officer | Jan 09 '24 | Option Exercise | 4.59 | 7,417 | 34,015 | 9,331 | Jan 11 07:59 PM | Krause Kevin Michael | Chief Strategy Officer | Jan 09 '24 | Sale | 20.14 | 7,417 | 149,367 | 1,914 | Jan 11 07:59 PM | Krause Kevin Michael | Chief Strategy Officer | Jan 02 '24 | Option Exercise | 0.42 | 2,583 | 1,085 | 4,497 | Jan 04 06:06 PM | Krause Kevin Michael | Chief Strategy Officer | Jan 02 '24 | Sale | 20.12 | 2,583 | 51,967 | 1,914 | Jan 04 06:06 PM | Easom Eric | Chief Executive Officer | Jan 02 '24 | Sale | 20.09 | 2,777 | 55,802 | 2,130 | Jan 04 06:05 PM |
|